Market Challenges And Opportunities

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Drivers

Increasing drug approvals by regulatory authorities is expected to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in March 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for Privigen, an immunoglobulin therapy for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. 207 patients were treated with Privigen for 13 weeks and 73% out of these 207 patients responded to it in clinical trials. Furthermore, in March 2018, CSL Behring received U.S. FDA approval for Hizentra, which is a type of subcutaneous immunoglobulin therapy that prevents relapsing neuromuscular disability. It offers a convenient treatment type, in which patients can infuse themselves. The approval was based on the phase III results of the clinical trial. These factors are expected to propel the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.

Moreover, there are several potential drugs in the pipeline for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). For instance, in January 2016, Shire plc, began clinical trials of HyQvia for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. HyQvia is a type of intravenous immunoglobulin therapy approved for the treatment of primary immunodeficiency and is currently in phase III of clinical trials for CIDP. Successful clinical trial completion and subsequent launch of these products is expected to boost global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.

Also, introduction of advanced technologies in diagnostic tools for chronic inflammatory demyelinating polyneuropathy (CIDP) disorder is expected to drive the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in July 2018, according to National Centre for Biotechnology Information (NCBI), multifocal visional evoked potential, a technique to diagnose CIDP is capable of detecting abnormalities in the optic nerve fiber, hence ensures higher accuracy in diagnosis. Therefore advancements in diagnostic tools of chronic inflammatory demyelinating polyneuropathy disorder are expected to support the growth of the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market.

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Restraints

Failure of the drugs in late stages of clinical trials has hampered the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, drugs such as Fingolimod (Gilenya, Novartis AG), and Acthar gel (Mallinckrodt Pharmaceuticals) indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) failed in the clinical trials in 2016, and 2018, respectively. These failures were associated with serious adverse events shown by these medications such as hypertension, extreme pain, fluid retention, alteration in glucose tolerance, and behavioral and mood changes.